Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

Publisher： Karger

E-ISSN： 1423-0232|75|3-4|215-223

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.3-4, 2008-10, pp. : 215-223

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 52-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 121-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 55-61

Karger

Access to resources Recommend Favorite